Glenmark Pharma Q4 Results: Profit declines 12.3% on higher input costs and lower demand

Glenmark Pharmaceuticals' Q4 consolidated profit before exceptional items and tax was INR3.09bn ($37.78m) for the quarter ended 31 March, down 12.3% compared to a year earlier, due to increased input costs and lower demand in the Indian drugs market. The firm posted one-time costs of INR8bn due to settlements over lawsuits in the US related to antitrust issues and consumer protection. While its sales rose 11.5%, the Indian drugs segment reported a 6.4% sales decline, accounting for 31% of its total, while North American sales grew by 15.3%.

Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.